Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $46.71.

Several equities research analysts have issued reports on the stock. Oppenheimer cut their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Mizuho reduced their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a "neutral" rating for the company in a research note on Thursday, October 24th. Citigroup decreased their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Needham & Company LLC dropped their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 6th.

Insider Activity at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the sale, the chief executive officer now directly owns 307,415 shares of the company's stock, valued at approximately $8,822,810.50. This trade represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Caroline Baumal sold 2,816 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. increased its position in Apellis Pharmaceuticals by 85.8% in the 4th quarter. Landscape Capital Management L.L.C. now owns 49,986 shares of the company's stock valued at $1,595,000 after acquiring an additional 23,086 shares during the period. Cinctive Capital Management LP acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $2,776,000. Trexquant Investment LP acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $6,478,000. Geode Capital Management LLC raised its position in Apellis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock worth $58,699,000 after purchasing an additional 28,426 shares during the last quarter. Finally, National Bank of Canada FI lifted its holdings in Apellis Pharmaceuticals by 266,361.5% during the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after buying an additional 1,385,080 shares during the period. Institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS traded down $0.02 during mid-day trading on Friday, reaching $28.51. 925,420 shares of the company were exchanged, compared to its average volume of 1,796,054. The stock has a market capitalization of $3.55 billion, a P/E ratio of -14.04 and a beta of 0.96. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company's 50-day simple moving average is $31.45 and its 200-day simple moving average is $32.30. Apellis Pharmaceuticals has a twelve month low of $24.34 and a twelve month high of $71.90.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).